Department of Epidemiology and Biostatistics, Amsterdam University Medical Centres, The Netherlands; Amsterdam Public Health Research Institute, The Netherlands.
Amsterdam Public Health Research Institute, The Netherlands; Department of General Practice, Amsterdam University Medical Centres, The Netherlands.
Sleep Med. 2018 Dec;52:51-57. doi: 10.1016/j.sleep.2018.07.022. Epub 2018 Aug 22.
Previous studies have investigated the association between sleep duration, insomnia, day-time napping and metabolic syndrome individually, but never conjointly. In addition, the association with sleep medication use has yet to be investigated. We aimed to examine the associations between these sleep-related characteristics and the metabolic syndrome, individually and conjointly, in a population-based cohort.
We used cross-sectional data of 1679 participants from the New Hoorn study, 52.6% women and age 60.8 + 6.4y. Sleep duration, insomnia, and day-time napping were measured using validated questionnaires. The use of sleep medication was documented by the registration of dispensing labels. The metabolic syndrome was defined according to ATP III. Linear and Poisson regressions were used, and all analyses were adjusted for age, sex, education level, job status, smoking, physical activity, depression and BMI.
In our population-based cohort, 447 (26.6%) persons had the metabolic syndrome. Individual associations showed that, after correction, day-time napping for ≤30 min and >30 min was associated with a prevalence ratio for the metabolic syndrome of 1.28 (95% CI: 1.1-1.5) and 1.74 (95% CI: 1.4-2.2), respectively, compared to participants who did not nap. Sleep duration, insomnia, and sleep medication use were not associated with the metabolic syndrome individually. However, conjointly analyses showed that, after correction, having ≥2 sleep-related characteristics was associated with a PR of 1.36 (95% CI: 1.0-1.8) of having the metabolic syndrome, compared to having no sleep-related characteristics.
Sleep-related characteristics were associated with a higher prevalence of the metabolic syndrome in the general population.
之前的研究分别调查了睡眠时长、失眠、白天小睡和代谢综合征之间的关联，但从未联合调查过。此外，睡眠药物使用与这些关联的关系也尚未被研究过。我们旨在通过基于人群的队列研究，单独和联合检查这些与睡眠相关的特征与代谢综合征之间的关联。
我们使用了新霍恩研究的 1679 名参与者的横断面数据，其中 52.6%为女性，年龄为 60.8±6.4 岁。使用经过验证的问卷来测量睡眠时长、失眠和白天小睡。睡眠药物的使用通过登记配药标签来记录。根据 ATP III 标准定义代谢综合征。使用线性和泊松回归进行分析，所有分析均根据年龄、性别、教育程度、工作状况、吸烟、身体活动、抑郁和 BMI 进行调整。
在我们的基于人群的队列中，447 人（26.6%）患有代谢综合征。个体关联分析表明，校正后，白天小睡≤30 分钟和＞30 分钟与代谢综合征的患病率比值分别为 1.28（95%CI：1.1-1.5）和 1.74（95%CI：1.4-2.2），与不午睡的参与者相比。睡眠时长、失眠和睡眠药物使用与代谢综合征之间均无关联。然而，联合分析显示，校正后，存在≥2 种与睡眠相关的特征与代谢综合征的患病率比值为 1.36（95%CI：1.0-1.8），与没有与睡眠相关的特征的参与者相比。
在一般人群中，与睡眠相关的特征与代谢综合征的患病率较高有关。
